Helix BioPharma Showcases CEACAM6-Targeting ADC Data at World ADC London Conference

Helix BioPharma Corp. presented new data on its CEACAM6-directed antibody-drug conjugate program at the 16th Annual World ADC London conference. The presentation, delivered by Jonathan Davis, PhD, Director of ADC Discovery at Helix BioPharma, focused on next-generation ADCs designed to target CEACAM6, a protein found in elevated levels across various epithelial cancers. The conference serves as a global forum for scientific exchange in ADC research and development, bringing together industry stakeholders from over 240 companies.

The presentation highlighted CEACAM6 as a highly attractive therapeutic target due to its elevated expression across a broad range of epithelial cancers, its association with poor clinical outcomes, and its limited expression in healthy tissues. Dr. Davis presented data supporting the tumor-selective binding profile of Helix's proprietary anti-CEACAM6 VHH, a single-domain antibody fragment derived from camelid antibodies. This nanobody demonstrated preferential binding to tumor-expressed CEACAM6, supporting the development of next-generation ADCs designed to deliver potent therapeutic payloads directly to cancer cells while minimizing off-target effects.

This research builds on the clinical foundation established by Tumor Defense Breaker L-DOS47, Helix's lead CEACAM6-targeted candidate, which has demonstrated favorable safety and encouraging clinical activity in Phase I/II studies in non-small cell lung cancer. The selective binding approach enables highly targeted therapy delivery, potentially improving treatment outcomes for patients with hard-to-treat cancers. A copy of the presentation is available on the company's website at https://helixbiopharma.com/wp-content/uploads/2026/02/Unlocking-the-Potential-of-CEACAM6.pdf.

Dr. Davis noted that CEACAM6 represents a compelling and underexploited target with broad potential across multiple hard-to-treat cancers. The proprietary VHH-based targeting approach enables highly selective tumor binding, supporting the development of next-generation ADCs designed to maximize therapeutic impact while minimizing off-target effects. The presentation generated strong interest and discussion among conference participants, reflecting growing recognition of CEACAM6 as an important emerging target in oncology. The World ADC London conference continues with a comprehensive scientific program covering advances in ADC discovery, development, and clinical translation, with more information available at https://worldadc-europe.com/.

The development of targeted therapies like CEACAM6-directed ADCs represents a significant advancement in oncology treatment strategies. By focusing on specific molecular targets overexpressed in cancer cells, these therapies aim to improve treatment precision and reduce side effects associated with traditional chemotherapy. The data presented at the conference contributes to the growing body of research supporting CEACAM6 as a viable target for cancer therapy development. This approach aligns with broader trends in personalized medicine and targeted cancer treatment, potentially offering new options for patients with limited therapeutic alternatives.